AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Von Willebrand Disease

Recent research efforts aimed at curing Von Willebrand Disease.

Last updated

Von Willebrand Disease

Overview

Von Willebrand disease (VWD) is an inherited bleeding disorder caused by too little von Willebrand factor (VWF) or by VWF that does not work properly. VWF helps platelets form an initial clot at an injured blood vessel and protects clotting factor VIII (FVIII) in the bloodstream. Symptoms range from easy bruising, nosebleeds, prolonged bleeding after dental work or surgery, and heavy menstrual bleeding to severe gastrointestinal, joint, or life-threatening bleeding in the rarest forms. Type 1 is a partial shortage of VWF, type 2 involves dysfunctional VWF, and type 3 is a near-complete absence of VWF. GeneReviews: Von Willebrand Disease Historical, current and future treatments for VWD

Prognosis is generally favorable with specialist care, although recurrent bleeding, iron deficiency, pregnancy-related bleeding, and treatment burden can substantially affect quality of life. Current care does not correct the inherited cause: it uses desmopressin to temporarily release stored VWF in people who respond to it, antifibrinolytic medicines such as tranexamic acid to stabilize clots, and plasma-derived or recombinant VWF concentrates for significant bleeding, surgery, or preventive treatment in severe disease. Orphanet: Von Willebrand disease ASH/ISTH/NHF/WFH management guideline

Scope of Recent Research (2020–present)

Research since 2020 has become more active and more molecularly targeted, but the field remains far behind hemophilia gene therapy. The central curative questions are whether investigators can safely restore normal VWF production in endothelial cells—the cells that normally make and store it—or selectively silence or repair a harmful VWF allele in dominant forms of disease. The most advanced genetic approaches remain preclinical; the only current early clinical programs are disease-modifying treatments that raise or preserve a person’s own VWF rather than permanently correcting the gene. Rewriting the script: gene therapy and genome editing for VWD Diagnosis and treatment of VWD in 2024 and beyond

Major Breakthroughs and Emerging Therapies

Gene addition is the most direct potential cure for type 3 VWD, where adding a working VWF gene could theoretically supply the missing protein long term. A major obstacle is size: the VWF coding sequence is about 8.4 kilobases, substantially larger than the payload that a conventional adeno-associated virus (AAV) vector can carry. In a notable 2023 study, researchers split VWF between two engineered AAV9 vectors, used an endothelial-cell promoter, and achieved long-term VWF expression after systemic administration in VWF-deficient mice. This was an important proof of principle, but VWF levels remained below those likely needed for clinical benefit. Dual hybrid AAV vector for endothelial-targeted VWF expression Historical, current and future treatments for VWD

Gene editing may be particularly promising for type 2 VWD caused by dominant-negative variants, in which the faulty VWF made by one gene copy disrupts protein made by the healthy copy. In a 2026 ex vivo study, investigators used CRISPR-Cas9 to selectively disrupt the mutant VWF allele in patient-derived endothelial colony-forming cells from people with type 2A or type 2B VWD. Rather than designing an editor for every disease-causing mutation, the team targeted a common linked single-letter DNA difference, preserving expression from the healthy allele; cellular disease features improved after editing. This is a meaningful advance toward a personalized, potentially one-time treatment, but it has not yet been tested as a therapy in animals or people. Allele-selective CRISPR disruption of pathogenic VWF variants

RNA silencing is a reversible alternative for dominant-negative disease. A 2025 mouse study delivered allele-selective small interfering RNA (siRNA) in endothelial-targeted lipid nanoparticles to reduce production of mutant VWF in a type 2B model. Treatment improved VWF multimer structure, collagen-binding activity, and bleeding time in two-thirds of treated mice. Because siRNA does not permanently edit DNA and may require repeated dosing, it is better viewed as a precision disease-modifying strategy than a cure; nevertheless, it shows that selectively suppressing mutant VWF can restore function even when total VWF falls. Allele-selective siRNA in a type 2B VWD mouse model

Several non-genetic therapies aim to reduce bleeding burden by increasing functional endogenous VWF. HMB-002 is a monoclonal antibody designed to bind the C-terminal region of VWF and increase its recycling through the neonatal Fc receptor pathway, thereby raising both VWF and FVIII levels without replacing VWF directly. BT200, now called rondoraptivon pegol, is an RNA aptamer that binds VWF’s A1 domain; low doses increased VWF and FVIII in early studies and showed potential utility in type 2B VWD, although higher doses can inhibit VWF-dependent platelet adhesion. These approaches may greatly improve prevention of bleeding but are not curative because they do not repair the inherited defect. HMB-002 Phase 1/2 study BT200 first-in-human trial Rondoraptivon pegol in type 2B VWD

Clinical Trials and Experimental Approaches

As of October 1, 2026, no VWD gene-transfer, gene-editing, or cell-therapy product has reported human clinical outcomes. The dual-AAV strategy, allele-selective CRISPR editing, and endothelial-targeted siRNA approaches are preclinical, using cell systems or mouse models. This distinction is important: these studies demonstrate biological feasibility, not safety, durability, or clinical benefit in people. Rewriting the script: gene therapy and genome editing for VWD Allele-selective CRISPR disruption of pathogenic VWF variants Allele-selective siRNA in a type 2B VWD mouse model

The leading disease-modifying clinical program is Hemab ApS’s VELORA Pioneer study of HMB-002, a recruiting first-in-human Phase 1/2, open-label dose-escalation trial in participants with VWD. The trial evaluates single and repeat subcutaneous doses for safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy; a separate cohort examines a dose given with standard VWF concentrate in people with severe residual deficiency. No definitive bleeding-prevention or long-term efficacy results have yet been reported in the registry. VELORA Pioneer: HMB-002 in VWD

Methodologies and Scientific Approaches

VWD cure research relies on patient-derived endothelial colony-forming cells, endothelial cell cultures, VWF-deficient and subtype-specific mouse models, and—historically—canine endothelial cells. These systems are used to test whether an intervention restores correctly assembled VWF multimers, secretion, storage, platelet binding, collagen binding, and clotting support for FVIII. The dual-AAV program tests endothelial-specific promoters and capsid engineering to direct treatment toward the cells that normally produce VWF, while siRNA studies use endothelial-directed lipid nanoparticles to deliver RNA cargo. Dual hybrid AAV vector for endothelial-targeted VWF expression Allele-selective siRNA in a type 2B VWD mouse model

Researchers measure success with VWF antigen and activity, FVIII activity, VWF multimer patterns, platelet counts, collagen-binding ratios, bleeding time or bleeding models, and molecular assays. The 2026 CRISPR study also used next-generation sequencing to quantify allele-selective editing and mass spectrometry capable of distinguishing mutant from normal VWF protein—important tools for proving that a therapy reduces the harmful protein while preserving the healthy version. Allele-selective CRISPR disruption of pathogenic VWF variants

Leading Institutions and Funding

Important academic centers include Leiden University Medical Center and Erasmus University Medical Center in the Netherlands, Sanquin Research and Amsterdam UMC, Université Paris-Saclay/INSERM in France, Queen’s University in Canada, and the University of Washington and Bloodworks Northwest in the United States. These groups contribute complementary expertise in VWF genetics, endothelial-cell biology, animal models, protein biochemistry, and clinical phenotyping. The NIH-funded Zimmerman Program for Molecular and Clinical Biology of VWD, including Program Project Grant P01HL144457, and the Canadian Institutes of Health Research Foundation Grant FDN 154285 are representative long-running collaborative programs supporting VWD genetics and translational research. Diagnosis and treatment of VWD in 2024 and beyond Zimmerman Program-supported VWF variant study

NHLBI also awarded Bloodworks Northwest an R35 Outstanding Investigator Award, R35HL177719, with an initial fiscal-year 2025 award of $1,276,908 for molecular and translational studies involving VWD and sickle cell disease. On the commercial side, Hemab is advancing HMB-002; the company reported a $157 million Series C financing in October 2025 to support its bleeding-disorder pipeline, including the VWD program. NHLBI award R35HL177719 Hemab Series C financing

Strengths, Limitations, and Challenges

The strongest recent progress is conceptual: researchers now have credible methods to address two distinct biological problems—replacing absent VWF in severe quantitative deficiency and selectively removing a harmful allele in dominant qualitative disease. Cell-based CRISPR results and mouse siRNA results show that correcting the balance between normal and mutant VWF can improve disease-relevant laboratory and bleeding measures. Allele-selective CRISPR disruption of pathogenic VWF variants Allele-selective siRNA in a type 2B VWD mouse model

The limitations are substantial. VWF is unusually large, complex, and normally made, multimerized, stored, and released by endothelial cells; simply producing protein in the liver may not recreate normal biology. Dominant VWD variants are highly diverse, making mutation-specific treatments difficult to scale, while permanent editing raises questions about delivery, off-target edits, immune responses, and lifelong safety. AAV vectors face cargo-size limits and pre-existing immunity, and even the promising dual-AAV mouse experiment produced too little VWF for likely clinical use. Access and affordability will also matter because individualized genomic treatments may be especially expensive for a genetically heterogeneous disorder. Dual hybrid AAV vector for endothelial-targeted VWF expression Historical, current and future treatments for VWD

Outlook and Future Directions

A true cure for VWD is not close to clinical practice as of October 1, 2026, but the pathway is clearer than it was in 2020. The most important milestones to watch are reproducible therapeutic VWF levels and normal multimer formation in large-animal or improved mouse studies; safe in vivo targeting of endothelial cells; confirmation that allele-selective RNA or CRISPR strategies work across multiple patient genotypes; and the first human safety trial of a genetic VWD therapy. In the nearer term, HMB-002 and other VWF-preserving agents may reduce bleeding and dependence on infusions, while gene addition and allele-selective editing remain longer-term candidates for durable, subtype-specific cures. Rewriting the script: gene therapy and genome editing for VWD VELORA Pioneer: HMB-002 in VWD

References

Don't see your disease? Request a report